A Randomized Phase II Trial of Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- 05 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 05 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 9 Jul 2019.
- 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.